Daily Stock Opinions and Ratings

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Opinions

Brooke Thackray Biogen IDEC Inc. BIIB-Q DON'T BUY Sep 24, 2019

The sector has done poorly, and the summer is seasonality. A lot of this has to do with the US election campaign with candidates offering cheap/free healthcare. BIIB fell below support at $250. He is avoiding the entire space.

Brooke Thackray

Unknown

Unlock Rating

$236.150

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly BIIB has been on a roller-coaster. When the FDA announced a priority review of a new Alzheimer's drug, it stock soared to $360. When the review failed to approve the drug in the first go-round, the stock plunged to under $250 -- so it goes with drug manufacturers. Its MS drugs continue to do well and it is working on treatments for Parkinson's disease as well. Trading at 8x earnings, it is cheap compared to peers at 30x. We would buy this with a $180 stop-loss looking to achieve $305 -- 26% upside. Yield 0%. (Analysts’ price target is $305.90)

DON'T BUY

Very high risk, very high reward. Seeing competition on its core drugs. Its Alzheimer's drug didn't get a great reception. Somewhere around June 7 the regulator will rule on this drug. Could be impacted 30% up or 50% down. Not for him.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 26.1%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CIEN has gapped up through the $305 target. To be disciplined, we recommend trailing up the stop (from $180) to $305. If triggered, this would all but guarantee a minimum investment return over 26%.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 43%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB is progressing well. We now recommend trailing up the stop (from $305) to $320. If triggered this would all but guarantee a investment return over 29%, when including the previous recommendation to cover half.

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 32.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BIIB has triggered its stop at $320. We recommend covering the position at this time. We will look for another entry point when value is justified again.

DON'T BUY

They own almost nothing in the Health Care space and Biotech is particularly weak.

BUY

The FDA figure who was key in getting their Alzheimer's drug recently left the FDA, but all the Alzheimer's plays declined except Biogen.

BUY

A great stock that whose Alzheimer drug will do well. (See also Eli Lilly.) Shares bounced along, but now picked up momentum.

COMMENT

They haven't launched their weight-loss drug yet, but the company's expects something big from it next year. The problem is that BIIB is lumped in with the general drug group.

DON'T BUY

Not impressed with products. Competitors out performing.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Brooke Thackray Biogen IDEC Inc. BIIB-Q DON'T BUY Sep 24, 2019

You might be interested:

This is a Panic-proof Portfolio opinion which is available only for Premium members

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Biogen IDEC Inc.(BIIB-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Biogen IDEC Inc.(BIIB-Q)

This is a Panic-proof Portfolio opinion which is available only for Premium members

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

Biogen IDEC Inc.(BIIB-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Greg Newman

Stockchase Insights

Jim Cramer - Mad Money

Brian Madden

The Panic-Proof Portfolio (Stockchase Research)